What's Happening?
Effective January 1, 2027, certain plans under CVS Caremark and Aetna will no longer cover Dexcom Continuous Glucose Monitors (CGMs) as a pharmacy benefit. This decision will require some Dexcom users to switch to Abbott’s FreeStyle Libre 3 Plus. Both
Dexcom G7 and Abbott FreeStyle Libre 3 Plus are advanced CGMs that provide real-time glucose readings, track trends, and alert users to high and low glucose levels. However, there are notable differences in sensor life, data frequency, warm-up time, connectivity, and insulin pump compatibility. For instance, Dexcom G7 has a faster 30-minute warm-up time and a predictive 'Urgent Low Soon' alert, while Libre 3 Plus offers glucose readings every minute and a longer sensor wear time of 15 days compared to Dexcom's 10 days. The Diabetes Patient Advocacy Coalition (DPAC) has launched an advocacy campaign in response, urging these providers to reconsider the forced non-medical switches and protect uninterrupted access to CGM technology.
Why It's Important?
This change is significant for individuals with diabetes, particularly those with Type 1 diabetes, who rely on CGMs for daily management. The forced switch can be disruptive, frustrating, and potentially consequential, as patients and caregivers become accustomed to specific device functionalities, alert systems, data sharing methods, and compatibility with automated insulin delivery (AID) systems. The issue extends beyond the technical specifications of the devices to the patient's ability to choose the technology that best suits their individual medical needs and lifestyle. Such insurance-mandated changes can create stress and anxiety, as learning a new device involves a significant learning curve, new prescriptions, and potential adjustments to established diabetes management routines. The move also raises questions about the influence of pharmacy benefit managers (PBMs) and insurers in dictating medical device choices, potentially prioritizing cost savings over patient-centered care.
What's Next?
Individuals affected by this change are advised to contact their doctors to discuss the transition and explore options for new prescriptions. If their prescriber agrees to the switch, a new prescription can be sent to the pharmacy to ensure coverage starting January 1, 2027, and avoid full out-of-pocket costs. Dexcom is working to assist affected customers with alternative coverage options and plans to introduce 'Dexcom Direct' in early 2027. The Diabetes Patient Advocacy Coalition (DPAC) is encouraging patients, caregivers, and advocates to participate in their letter-writing campaign to CVS Caremark and Aetna, advocating for patient choice and uninterrupted access to CGM technology. Further research and advocacy efforts will likely continue to address the broader implications of insurance formulary decisions on patient care and technology access.
Beyond the Headlines
The situation highlights a broader ethical and policy debate regarding patient autonomy versus insurance formulary decisions in healthcare. While both Dexcom G7 and FreeStyle Libre 3 Plus are effective CGMs, the lack of patient choice in selecting a device that integrates seamlessly with their existing diabetes management routine, including insulin pumps and data sharing with caregivers, can have profound impacts on quality of life and health outcomes. This development could set a precedent for how insurance companies dictate access to other medical technologies, potentially leading to a more standardized, but less personalized, approach to chronic disease management. The emphasis on cost-effectiveness by PBMs and insurers, without fully accounting for individual patient needs and established routines, could lead to increased patient burden and potentially suboptimal health outcomes for a vulnerable population.













